Supplementary Tables 1-2 from the CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis

Wei Zhuo,Jenshan Lin,Nan Song,Xiangjun Lu,Yanping Ding,Xiaofeng Wang,Xiaomin Song,Fei Yan,Yongzhang Luo

DOI: https://doi.org/10.1158/1078-0432.22452032

2023-01-01

Abstract:PDF file - 141K, S1. Primers for qRT-PCR; S2. The expression level of CXCL12 and the lymphatic vessel density in the human tissue microarray

What problem does this paper attempt to address?

Data from the CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis

Wei Zhuo,Lin Jia,Nan Song,Xin-an Lu,Yanping Ding,Xiaofeng Wang,Xiaomin Song,Yan Fu,Yongzhang Luo

DOI: https://doi.org/10.1158/1078-0432.c.6522368.v1

2023-01-01

Abstract:Abstract Purpose: Lymphangiogenesis, the growth of lymphatic vessels, contributes to lymphatic metastasis. However, the precise mechanism underlying lymphangiogenesis remains poorly understood. This study aimed to examine chemokine/chemokine receptors that directly contribute to chemoattraction of activated lymphatic endothelial cells (LEC) and tumor lymphangiogenesis. Experimental Design: We used quantitative RT-PCR to analyze specifically expressed chemokine receptors in activated LECs upon stimulation of vascular endothelial growth factor-C (VEGF-C). Subsequently, we established in vitro and in vivo models to show lymphangiogenic functions of the chemokine axis. Effects of targeting the chemokine axis on tumor lymphangiogenesis and lymphatic metastasis were determined in an orthotopic breast cancer model. Results: VEGF-C specifically upregulates CXCR4 expression on lymphangiogenic endothelial cells. Moreover, hypoxia-inducible factor-1α (HIF-1α) mediates the CXCR4 expression induced by VEGF-C. Subsequent analyses identify the ligand CXCL12 as a chemoattractant for LECs. CXCL12 induces migration, tubule formation of LECs in vitro, and lymphangiogenesis in vivo. CXCL12 also stimulates the phosphorylation of intracellular signaling Akt and Erk, and their specific antagonists impede CXCL12-induced chemotaxis. In addition, its level is correlated with lymphatic vessel density in multiple cancer tissues microarray. Furthermore, the CXCL12–CXCR4 axis is independent of the VEGFR-3 pathway in promoting lymphangiogenesis. Intriguingly, combined treatment with anti-CXCL12 and anti-VEGF-C antibodies results in additive inhibiting effects on tumor lymphangiogenesis and lymphatic metastasis. Conclusions: These results show the role of the CXCL12–CXCR4 axis as a novel chemoattractant for LECs in promoting lymphangiogenesis, and support the potential application of combined targeting of both chemokines and lymphangiogenic factors in inhibiting lymphatic metastasis. Clin Cancer Res; 18(19); 5387–98. ©2012 AACR.
The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.

Wei Zhuo,Lin Jia,Nan Song,Xin-An Lu,Yanping Ding,Xiaofeng Wang,Xiaomin Song,Yan Fu,Yongzhang Luo

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0708

IF: 13.801

2012-01-01

Clinical Cancer Research

Abstract:Purpose: Lymphangiogenesis, the growth of lymphatic vessels, contributes to lymphatic metastasis. However, the precise mechanism underlying lymphangiogenesis remains poorly understood. This study aimed to examine chemokine/chemokine receptors that directly contribute to chemoattraction of activated lymphatic endothelial cells (LEC) and tumor lymphangiogenesis. Experimental Design: We used quantitative RT-PCR to analyze specifically expressed chemokine receptors in activated LECs upon stimulation of vascular endothelial growth factor-C (VEGF-C). Subsequently, we established in vitro and in vivo models to show lymphangiogenic functions of the chemokine axis. Effects of targeting the chemokine axis on tumor lymphangiogenesis and lymphatic metastasis were determined in an orthotopic breast cancer model. Results: VEGF-C specifically upregulates CXCR4 expression on lymphangiogenic endothelial cells. Moreover, hypoxia-inducible factor-1 alpha (HIF-1 alpha) mediates the CXCR4 expression induced by VEGF-C. Subsequent analyses identify the ligand CXCL12 as a chemoattractant for LECs. CXCL12 induces migration, tubule formation of LECs in vitro, and lymphangiogenesis in vivo. CXCL12 also stimulates the phosphorylation of intracellular signaling Akt and Erk, and their specific antagonists impede CXCL12-induced chemotaxis. In addition, its level is correlated with lymphatic vessel density in multiple cancer tissues microarray. Furthermore, the CXCL12-CXCR4 axis is independent of the VEGFR-3 pathway in promoting lymphangiogenesis. Intriguingly, combined treatment with anti-CXCL12 and anti-VEGF-C antibodies results in additive inhibiting effects on tumor lymphangiogenesis and lymphatic metastasis. Conclusions: These results show the role of the CXCL12-CXCR4 axis as a novel chemoattractant for LECs in promoting lymphangiogenesis, and support the potential application of combined targeting of both chemokines and lymphangiogenic factors in inhibiting lymphatic metastasis. Clin Cancer Res; 18(19); 5387-98. (C)2012 AACR.
Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Binghao Li,Zhan Wang,Hao Wu,Mingfeng Xue,Peng Lin,Shengdong Wang,Nong Lin,Xin Huang,Weibo Pan,Meng Liu,Xiaobo Yan,Hao Qu,Lingling Sun,Hengyuan Li,Yan Wu,Wangsiyuan Teng,Zenan Wang,Xingzhi Zhou,Huabiao Chen,Mark C. Poznansky,Zhaoming Ye

DOI: https://doi.org/10.1158/0008-5472.22419831

2023-01-01

Abstract:Supplementary Table S1. Primers for qRT-PCR and MSP
Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Qiang Gao,Yingjun Zhao,Xiaoying Wang,Shuang‐Jian Qiu,Ying‐Hong Shi,Jun Sun,Yi Yao,Jing Shi,Guo‐Ming Shi,Zhen–Bin Ding,Xiao Ye,Zhao Zhen,Jing Zhou,Xiayun He,Jia Fan

DOI: https://doi.org/10.1158/0008-5472.22391669

2023-01-01

Abstract:PDF file - 856K, Effects of CXCL16-knockdown on HCC cell invasion and cytokine secretion in vitro, and tumor growth in vivo
Supplementary Data 3 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Xin Zhang,Limei Guo,Wenyu Tian,Ying Yang,Yue Yin,Yaruo Qiu,Weixuan Wang,Yang Li,Guangze Zhang,Xuyang Zhao,Guangxi Wang,Zhiqiang Lin,Meng Yang,Wei Zhao,Dan Lu

DOI: https://doi.org/10.1158/2326-6066.27601939

2024-01-01

Abstract:Table S1 Primers used for quantitative real-time PCR.
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Figure 2 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Qiang Gao,Ying-Jun Zhao,Xiao-Ying Wang,Shuang-Jian Qiu,Ying-Hong Shi,Jian Sun,Yong Yi,Jie-Yi Shi,Guo-Ming Shi,Zhen-Bin Ding,Yong-Sheng Xiao,Zhong-Hua Zhao,Jian Zhou,Xiang-Huo He,Jia Fan

DOI: https://doi.org/10.1158/0008-5472.22391672.v1

2023-01-01

Abstract:PDF file - 656K, CXCL16 expression in HCC and its relationship with clinical outcome
Supplementary Figure 1 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Qiang Gao,Yingjun Zhao,Xiaoying Wang,Shuang–Jian Qiu,Ying‐Hong Shi,Jing Sun,Yi Yao,Jing Shi,Guo‐Ming Shi,Zhen–Bin Ding,Xiao Ye,Zhao Zhen,Jing Zhou,Xiayun He,Jia Fan

DOI: https://doi.org/10.1158/0008-5472.22391675

2023-01-01

Abstract:PDF file - 2.4MB, Western blotting analysis of CXCR6 and CXCL16 in HCC and peritumoral liver tissues
Supplementary Figures 1-10 from CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma

Pierre Saintigny,Erminia Massarelli,Steven Lin,Young-Ho Ahn,Yulong Chen,Sangeeta Goswami,Baruch Erez,Michael S. O'Reilly,Diane Liu,J. Jack Lee,Li Zhang,Yuan Ping,Carmen Behrens,Luisa M. Solis Soto,John V. Heymach,Edward S. Kim,Roy S. Herbst,Scott M. Lippman,Ignacio I. Wistuba,Waun Ki Hong,Jonathan M. Kurie,Ja Seok Koo

DOI: https://doi.org/10.1158/0008-5472.22394124

2023-01-01

Abstract:PDF file - 581K, Supplementary Figure 1: Distribution of cytoplasmic CXCR2 protein expression in 262 non-small cell lung cancer cell lines. Supplementary Figure 2: CXCR2 expression in tumor cells according to EGFR and KRAS mutation status. Supplementary Figure 3: Kaplan-Meier curves Supplementary Figure 4: Distribution of expression of CXCR2 and its ligand genes Supplementary Figure 5: CXCR2/CXCR2 ligands cluster is associated with a worse overall survival in patients with lung adenocarcinoma (N=442) Supplementary Figure 6: TTF-1 gene expression was more frequently lower in lung adenocarcinomas Supplementary Figure 7: The first two principal components were computed using expression of CXCR2 and its ligand genes Supplementary Figure 8: The first two principal components were computed using expression of CXCR2 and its ligand genes Supplementary Figure 9: Expression of (A) CXCL1, (B) CXCL2, (C) CXCL3, and (D) CXCL6 genes was negatively correlated with the level of their promoter methylation as indicated by average beta-value. Supplementary Figure 10: The effect of two doses of decitabine
Supplementary Figure 1 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Jian Ye,Chunling Ma,Fang Wang,Eddy C. Hsueh,Karoly Toth,Yi Huang,Wei Mo,Shuai Liu,Bing Han,Mark A. Varvares,Daniel F. Hoft,Guangyong Peng

DOI: https://doi.org/10.1158/0008-5472.22396604.v1

2023-01-01

Abstract:PDF file, 944K, IP-10 is the only functional chemokine inducing the migration of Treg cells.
Supplementary Figure Legends 1-3, Table 1 from the Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms

Sool Yeon Cho,Mingjiang Xu,John Roboz,Min Lu,John Mascarenhas,Ronald Hoffman

DOI: https://doi.org/10.1158/0008-5472.22386186.v1

2023-01-01

Abstract:Supplementary Figure Legends 1-3, Table 1 from The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms
Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Qiang Gao,Ying-Jun Zhao,Xiao-Ying Wang,Shuang-Jian Qiu,Ying-Hong Shi,Jian Sun,Yong Yi,Jie-Yi Shi,Guo-Ming Shi,Zhen-Bin Ding,Yong-Sheng Xiao,Zhong-Hua Zhao,Jian Zhou,Xiang-Huo He,Jia Fan

DOI: https://doi.org/10.1158/0008-5472.22391666.v1

2023-01-01

Abstract:PDF file - 1.6MB, The effects CXCR6-konckdown on expression of epithelial-to-mesenchymal transition markers and signaling molecules of hepatoma cells
Microarray analysis to explore the effect of CXCL12 isoforms in a pancreatic pre-tumor cell model

Yan-Dong Miao,Jiang-Tao Wang,Xiao-Long Tang,Deng-Hai Mi

DOI: https://doi.org/10.3748/wjg.v27.i47.8194

IF: 5.374

2021-12-21

World Journal of Gastroenterology

Abstract:CXCL12 expression was significantly lower in tumor samples than in corresponding normal samples. CXCL12 expression was significantly positively related to the infiltration levels of T cells, dendritic cells (DCs), immature DCs, cytotoxic cells, Tfh cells, mast cells, B cells, Th1 cells, natural killer (NK) cells, pDCs, neutrophils, and T helper cells (Spearman correlation coefficient > 0.5, P < 0.001) and negatively correlated with the infiltration level of NK CD56bright cells. In addition, pancreatic hTERT-HPNE cells treated with three diverse CXCL12 isoforms exhibited changes mainly in the regulation of the epithelial-mesenchymal transition activation pathway.

gastroenterology & hepatology
Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Ling-Min Kong,Cheng-Gong Liao,Yang Zhang,Jing Xu,Yu Li,Wan Huang,Yi Zhang,Huijie Bian,Zhi-Nan Chen

DOI: https://doi.org/10.1158/0008-5472.22402862

2023-01-01

Abstract:PDF file - 75K, Oligonucleotide sequence of PCR primers and siRNA fragments.
Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Nisha Nagarsheth,Dongjun Peng,Ilona Kryczek,Ke Wu,Wei Li,Ende Zhao,Lili Zhao,Shuang Wei,Timothy Frankel,Linda Vatan,Wojciech Szeliga,Yali Dou,Scott Owens,Victor Marquez,Kaixiong Tao,Emina Huang,Guobin Wang,Weiping Zou

DOI: https://doi.org/10.1158/0008-5472.22409408.v1

2023-01-01

Abstract:This is Supplementary Tables I and II Table 1: RT-PCR primers and ChIP primers Table 2: shRNA Sequences
Supplementary Figures 1 - 7 from CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

Yuting Ma,Stephen R. Mattarollo,Sandy Adjemian,Heng Yang,Laetitia Aymeric,Dalil Hannani,João Paulo Portela Catani,Helene Duret,Michele W.L. Teng,Oliver Kepp,Yidan Wang,Antonella Sistigu,Joachim L. Schultze,Gautier Stoll,Lorenzo Galluzzi,Laurence Zitvogel,Mark J. Smyth,Guido Kroemer

DOI: https://doi.org/10.1158/0008-5472.22401329.v1

2023-01-01

Abstract:PDF file - 544K, Influence of anthracycline-based chemotherapy on myeloid cells in distinct lymphoid organs (S1); Impact of chemotherapy on the expression of M1 and M2 macrophage-related genes by Ly6Chigh cells (S2); Anthracycline-based chemotherapy activates antigen-specific T cells within neoplastic lesions (S3); Anthracycline-based chemotherapy fails to affect the proliferation of antigen-specific T cells within tumor draining lymph nodes (S4); Anthracycline-based chemotherapy induces fluctuations in the circulating levels of various myeloid cell populations (S5); Chemotherapy regulates the expression of chemokine-encoding genes by tumor-infiltrating leukocytes (S6); Expression of Ccr2 on malignant cells and tumor-infiltrating CD11b+ cells (S7).
Supplementary Table S2 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Xin Zhang,Limei Guo,Wenyu Tian,Ying Yang,Yue Yin,Yaruo Qiu,Weixuan Wang,Yang Li,Guangze Zhang,Xuyang Zhao,Guangxi Wang,Zhiqiang Lin,Meng Yang,Wei Zhao,Dan Lu

DOI: https://doi.org/10.1158/2326-6066.27601852

2024-01-01

Abstract:Supplementary Table S2 Clinicopathological characteristics of patients for scRNA-seq data.
The Hematopoietic Chemokine CXCL12 Promotes Integration of Human Endothelial Colony Forming Cell-Derived Cells into Immature Vessel Networks.

Sarah E. Newey,Grigorios Tsaknakis,Cheen P. Khoo,Thanassi Athanassopoulos,Rosalba Camicia,Youyi Zhang,Rita Grabowska,Adrian L. Harris,Maria G. Roubelakis,Suzanne M. Watt

DOI: https://doi.org/10.1089/scd.2014.0005

2014-01-01

Stem Cells and Development

Abstract:Proangiogenic factors, vascular endothelial growth factor (VEGF), and fibroblast growth factor-2 (FGF-2) prime endothelial cells to respond to "hematopoietic" chemokines and cytokines by inducing/upregulating expression of the respective chemokine/cytokine receptors. Coculture of human endothelial colony forming cell (ECFC)-derived cells with human stromal cells in the presence of VEGF and FGF-2 for 14 days resulted in upregulation of the "hematopoietic" chemokine CXCL12 and its CXCR4 receptor by day 3 of coculture. Chronic exposure to the CXCR4 antagonist AMD3100 in this vasculo/angiogenesis assay significantly reduced vascular tubule formation, an observation recapitulated by delayed AMD3100 addition. While AMD3100 did not affect ECFC-derived cell proliferation, it did demonstrate a dual action. First, over the later stages of the 14-day cocultures, AMD3100 delayed tubule organization into maturing vessel networks, resulting in enhanced endothelial cell retraction and loss of complexity as defined by live cell imaging. Second, at earlier stages of cocultures, we observed that AMD3100 significantly inhibited the integration of exogenous ECFC-derived cells into established, but immature, vascular networks. Comparative proteome profiler array analyses of ECFC-derived cells treated with AMD3100 identified changes in expression of potential candidate molecules involved in adhesion and/or migration. Blocking antibodies to CD31, but not CD146 or CD166, reduced the ECFC-derived cell integration into these extant vascular networks. Thus, CXCL12 plays a key role not only in endothelial cell sensing and guidance, but also in promoting the integration of ECFC-derived cells into developing vascular networks.
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Xueqing Sun,Guangcun Cheng,Mingang Hao,Jianghua Zheng,Xiaoming Zhou,Jian Zhang,Russell S. Taichman,Kenneth J. Pienta,Jianhua Wang

DOI: https://doi.org/10.1007/s10555-010-9256-x

2010-01-01

Cancer and Metastasis Reviews

Abstract:Chemokines, small pro-inflammatory chemoattractant cytokines that bind to specific G-protein-coupled seven-span transmembrane receptors, are major regulators of cell trafficking and adhesion. The chemokine CXCL12 (also called stromal-derived factor-1) is an important α-chemokine that binds primarily to its cognate receptor CXCR4 and thus regulates the trafficking of normal and malignant cells. For many years, it was believed that CXCR4 was the only receptor for CXCL12. Yet, recent work has demonstrated that CXCL12 also binds to another seven-transmembrane span receptor called CXCR7. Our group and others have established critical roles for CXCR4 and CXCR7 on mediating tumor metastasis in several types of cancers, in addition to their contributions as biomarkers of tumor behavior as well as potential therapeutic targets. Here, we review the current concepts regarding the role of CXCL12 / CXCR4 / CXCR7 axis activation, which regulates the pattern of tumor growth and metastatic spread to organs expressing high levels of CXCL12 to develop secondary tumors. We also summarize recent therapeutic approaches to target these receptors and/or their ligands.
Regulative Role of the CXCL13-CXCR5 Axis in the Tumor Microenvironment

Ping Tan,Ming Shi,Li Lai,Zhuang Tang,Nan Xie,Hang Xu,Qiang Wei,Xiaoyu Zhang,Lu Yang,Lily Wu

DOI: https://doi.org/10.1093/pcmedi/pby006

2018-01-01

Precision Clinical Medicine

Abstract:Chemokines are best known for their abilities of recruiting immune cells and forming lymphoid tissue. Through interactions between chemokines and their receptors, various immune cell subsets are recruited into the tumor microenvironment which is the primary location for tumor cells interacting with responding host cells. In recent decades, a large volume of studies have revealed chemokines' role in the tumor microenvironment in regulating tumor growth, invasion, and/or metastasis as well as tumor immune response; however, their molecular mechanisms are not well understood. Recently, increasing evidence has reported the importance of the CXCL13-CXCR5 axis in the tumor microenvironment of various human malignancies. Thus, in this review, we will focus on the CXCL13-CXCR5 axis and elaborate on the expression patterns, regulating and corresponding regulatory mechanisms as well as clinical values in a wide range of human cancers.

Supplementary Tables 1-2 from the CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis

Data from the CXCL12–CXCR4 Chemokine Pathway: A Novel Axis Regulates Lymphangiogenesis

The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.

Table S1 from Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Data 3 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133&lt;sup&gt;+&lt;/sup&gt; Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Figure 2 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Figure 1 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Supplementary Figures 1-10 from CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma

Supplementary Figure 1 from Specific Recruitment of Γδ Regulatory T Cells in Human Breast Cancer

Supplementary Figure Legends 1-3, Table 1 from the Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms

Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma

Microarray analysis to explore the effect of CXCL12 isoforms in a pancreatic pre-tumor cell model

Supplementary Table 1 from A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

Supplementary Table I and II from PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

Supplementary Figures 1 - 7 from CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy

Supplementary Table S2 from CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence

The Hematopoietic Chemokine CXCL12 Promotes Integration of Human Endothelial Colony Forming Cell-Derived Cells into Immature Vessel Networks.

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

Regulative Role of the CXCL13-CXCR5 Axis in the Tumor Microenvironment

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma